Key result
Rivaroxaban at 20 mg per day prevented catheter-associated thrombosis compared to no prophylaxis (0% vs 15.7%, RR 0.86) in breast cancer patients with central venous catheters.
Why the study?
Catheter-associated thrombosis is a common complication in cancer patients, prompting evaluation of the efficacy and safety of thromboprophylaxis with rivaroxaban.
Does prophylactic rivaroxaban prevent catheter-associated thrombosis in breast cancer patients with central venous catheters?
RCT (n=38)
Randomized
Yes
Does prophylactic rivaroxaban prevent catheter-associated thrombosis in breast cancer patients with central venous catheters?
Relative Risk: 0.86
Absolute Event Rate: 0% vs 15.7%
Prophylactic use of rivaroxaban 20 mg daily may effectively prevent central venous catheter-associated thrombosis in breast cancer patients without increasing the risk of major bleeding.
May support rivaroxaban for catheter thrombosis prevention; hypothesis-generating and requires randomized confirmation before practice change.
Central venous catheters (CVCs), such as the tunneled catheters and the totally implanted ports, play a major role in general medicine and oncology. Thrombosis associated with CVCs is a common complication in cancer patients. Thus, in order to more widely study the problem of catheter-associated thrombosis in cancer patients, we initiated a study for 2022-2023 within one region. Purpose. Evaluation of the efficacy and safety of thromboprophylaxis of catheter-associated thrombosis with rivaroxaban in cancer patients. Material and methods. Prospective multicenter study, conducted since 01/05/2022 and planned to be completed by the end of 2022, on the basis of three centers. The subjects are divided into 2 groups to randomize 60 participants in each. The first group: receive DOACs (rivaroxaban) at a dosage of 20 mg per day the day before the inserting of the CVC. Second group: treatment of the underlying disease without the use of DOACs. Results. None of the patients developed submassive or massive pulmonary embolism. There were no cases of CAT in the thromboprophylaxis group compared to the non-thrombotic prophylaxis group (0% vs 15.7%). The relative risk of developing CAT is 0.86, which indicates the effectiveness of thromboprophylaxis with rivaroxaban. Conclusion. Our interim results show the efficacy of rivaroxaban at a dosage of 20 mg per day in cancer patients. The final results are planned to be published at the end of the study
No takes yet. Share an insight, caveat, or question.
Tajibayev et al. (2022) conducted an RCT in Malignant neoplasms of the breast with inserted central venous catheter (CVC) (n=38). Rivaroxaban vs. No thromboprophylaxis was evaluated on Catheter-associated thrombosis (CAT) (RR 0.86). Rivaroxaban at 20 mg per day prevented catheter-associated thrombosis compared to no prophylaxis (0% vs 15.7%, RR 0.86) in breast cancer patients with central venous catheters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: